NOV 18, 2019 8:37 PM PST

FDA Approves New Drug for Sickle Cell Disease

WRITTEN BY: Annie Lennon

Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting it out of reach of most, with other ways of managing the disease limited to preventative care. Now however, how these symptoms are managed may change with the FDA approval of the first ever targeted therapy for Sickle Cell Disease, Adakveo, developed by pharmaceutical company, Novartis. 

Normally, red blood cells are disk-like in shape. However, due to a genetic mutation for those with Sickle Cell Disease, their red blood cells resemble C-shaped crescents of “sickles”. Due to their shape, they often get stuck to the walls of blood vessels where they cause blockages. This may then result in vaso-occlusive crises in which blood flow to certain parts of the body is blocked (Lee: 2019). 

Leading to severe pain and potential organ damage due to deprivation of oxygen, until now, the only way to manage such crises has been to avoid certain triggers, such as high elevation, extreme cold, physical exhaustion and certain drugs such as acetazolamide. 

Now however, with Adakveo, also known as crizanlizumab-tmca, people with the disease may have another option. For those affected, a protein known as P-selectin found on the cellular lining inside blood vessel walls and platelets enables crescent-shaped red blood cells to stick to blood vessel walls, thus causing blockages. Adakveo works against ths by binding to and blocking P-selectin, thus preventing blockages and preventing vaso-occlusive crises (ibid.). 

The drug’s approval comes following results from a randomized clinical trial of 198 participants. There, researchers showed those who received Adakveo required an average of 1.63 hospital visits per year, whereas those on a placebo required an average of 2.98. The trial also found that those taking the drug had a longer time until experiencing their first vaso-occlusive crisis, and that 36% of those on the drug didn’t have a vaso-occlusive crisis at all throughout the study’s duration (FDA: 2019). 

According to Kenneth I. Attaga MD, director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center at Memphis, “We know this drug can decrease the frequency of sickle cell pain crisis in a significant and clinically meaningful way...The approval of crizanlizumab is an important advancement for people living with this very difficult condition (Kunzmann: 2019).”

 

Sources

 

Lee, Bruce: Forbes

FDA News

Kunzmann, Kevin: MDmag

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 06, 2022
Drug Discovery & Development
Scientists discover new methods of production for Sulphur-based medications
MAY 06, 2022
Scientists discover new methods of production for Sulphur-based medications
Modern medicine has drastically changed since humans discovered the first ancient treatment methods. Herbal remedies and ...
MAY 09, 2022
Cancer
A Gel Implant Protects from Cancer Recurrence
MAY 09, 2022
A Gel Implant Protects from Cancer Recurrence
Following a successful course of cancer treatment, a patient may enter remission. Remission, classified as either partia ...
JUN 02, 2022
Drug Discovery & Development
NSAIDs Can Have Different, Unexpected Effects on People. Why?
JUN 02, 2022
NSAIDs Can Have Different, Unexpected Effects on People. Why?
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common types of drugs used to treat pain and inflammat ...
JUN 14, 2022
Cancer
Maintaining Sample Temperature: Q&A From a Corning Scientist
JUN 14, 2022
Maintaining Sample Temperature: Q&A From a Corning Scientist
Generally speaking, bad things can happen when a cell sample temperature gets too hot or too cold. Temperature instabili ...
JUN 11, 2022
Drug Discovery & Development
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
JUN 11, 2022
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
Inhaled aerosol vaccines provide more protection than nasal sprays and evoke a stronger immune response. The correspondi ...
JUN 24, 2022
Cannabis Sciences
Decrease in Youth Substance Use During the Pandemic
JUN 24, 2022
Decrease in Youth Substance Use During the Pandemic
A review published in Child and Family Disaster Psychiatry found that youth substance use declined during the COVID-19 p ...
Loading Comments...